Hormone · FDA Approved
Pegvisomant (Somavert)
FDA-approved
01 · Overview
Pegvisomant is a PEGylated growth hormone receptor antagonist engineered from human growth hormone with amino acid substitutions that confer antagonist properties. The molecule binds to growth hormone receptors without activating downstream signaling, blocking the action of endogenous growth hormone (PMID 10770982).
It is indicated for acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate.
02 · Research summary & key findings
In a 12-week randomized, placebo-controlled trial published in the New England Journal of Medicine in 2000, IGF-1 normalized in up to 89 percent of patients at the highest daily dose, with improvements in signs and symptoms (PMID 10770982). In longer-term treatment, 97 percent of patients treated for 12 months or more achieved normal IGF-1 (PMID 11734231). In the real-world ACROSTUDY of 2,090 patients, the proportion with normal IGF-1 rose from 53 percent at year 1 to 73 percent at year 10, and liver enzyme elevations above three times normal occurred in 3 percent (PMID 30325178). The FDA approved pegvisomant in 2003.
03 · Regulatory status
Pegvisomant (Somavert) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Pegvisomant (Somavert) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Pegvisomant (Somavert) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med, 2000. PMID 10770982
- [2]Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet, 2001. PMID 11734231
- [3]Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY Eur J Endocrinol, 2018. PMID 30325178
Primary literature
- PubMed: "Pegvisomant"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Pegvisomant"
Registered interventional and observational studies, including status and phase.
- PubChem: "Pegvisomant"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.